Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **Protocolized Diuretic Strategy (ProDiuS)** is a standardized clinical intervention protocol developed for the management of fluid overload in patients with **cardiorenal syndrome** (combined heart and kidney failure). Led by **Kelly V. Liang, MD**, at the University of Pittsburgh, the strategy utilizes a 'stepped pharmacologic care' algorithm to overcome diuretic resistance. The protocol involves the aggressive administration of **loop diuretics** (such as **furosemide**) via intravenous bolus followed by continuous infusion, with the potential addition of **thiazide diuretics** (such as oral **metolazone** or intravenous **chlorothiazide**). The primary goal of ProDiuS is to achieve a target urine output of 3-5 liters per day, thereby improving decongestion, reducing hospital length of stay, and enhancing health-related quality of life (HRQOL) compared to non-standardized usual care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Protocolized Diuretic Strategy.